Christine Wilson, cancer survivor, shares her experiences from the Focus On Melanoma conference in the third in a series of four blog posts.
One of the key concepts in medicine today is "personalized medicine." What few people may realize is that the emerging ability to talk about individual profiles for specific cancers results entirely from the type of research being done by people like Jessie Villaneuva, PhD, and Robert Vonderheide, MD. Drs. Villaneuva and Vonderheide presented highlights of their research at the Abramson Cancer Center's Focus On Melanoma Conference.
In the last few years, it has become possible to begin identifying subsets of patients based on the molecular characteristics of their cancers, and tailor new treatments to match those specific profiles.
Identifying these molecular characteristics is critical in treating many cancers, and increasingly so in melanoma. Mutations in the BRAF gene occur in approximately 50 percent of patients with advanced melanoma and provide a valuable target for new therapies. These therapies, however, are only effective for those who have the BRAF mutation. The same principle holds true for other less frequent mutations.
Finding this target has major implications for both developing new drugs and for delivering treatment to patients with melanoma. It means more drugs are needed to hit multiple targets and that new drugs are likely to be more potent and more specific. They will work better and be less toxic but in smaller populations of patients. It also makes it critical that patients be aware of the need to collect sufficient tumor tissue to allow for molecular profiling of their tumor so they can receive the therapies designed to work best for their type of cancer. Tissue collection is vital both at the time of diagnosis and if and when metastatic disease occurs as cancers often change their genetic profiles as they grow and spread.
For more information, view the Focus On Melanoma conference video and Melanoma Treatment: A Patient Video Guide, on the ACC website.
Learn more about melanoma treatment at Penn Medicine.
One of the key concepts in medicine today is "personalized medicine." What few people may realize is that the emerging ability to talk about individual profiles for specific cancers results entirely from the type of research being done by people like Jessie Villaneuva, PhD, and Robert Vonderheide, MD. Drs. Villaneuva and Vonderheide presented highlights of their research at the Abramson Cancer Center's Focus On Melanoma Conference.
In the last few years, it has become possible to begin identifying subsets of patients based on the molecular characteristics of their cancers, and tailor new treatments to match those specific profiles.
Identifying these molecular characteristics is critical in treating many cancers, and increasingly so in melanoma. Mutations in the BRAF gene occur in approximately 50 percent of patients with advanced melanoma and provide a valuable target for new therapies. These therapies, however, are only effective for those who have the BRAF mutation. The same principle holds true for other less frequent mutations.
Finding this target has major implications for both developing new drugs and for delivering treatment to patients with melanoma. It means more drugs are needed to hit multiple targets and that new drugs are likely to be more potent and more specific. They will work better and be less toxic but in smaller populations of patients. It also makes it critical that patients be aware of the need to collect sufficient tumor tissue to allow for molecular profiling of their tumor so they can receive the therapies designed to work best for their type of cancer. Tissue collection is vital both at the time of diagnosis and if and when metastatic disease occurs as cancers often change their genetic profiles as they grow and spread.
For more information, view the Focus On Melanoma conference video and Melanoma Treatment: A Patient Video Guide, on the ACC website.
Learn more about melanoma treatment at Penn Medicine.
